Over the last 7 days, the United States market has risen 2.6% and is up 26% over the last 12 months, with earnings forecasted to grow by 17% annually. In this favorable environment, growth companies with strong insider ownership can be particularly appealing as they often align management's interests with those of shareholders, potentially driving long-term value creation.
Over the last 7 days, the United States market has risen 2.6% and is up 26% over the last 12 months, with earnings forecasted to grow by 17% annually. In this favorable environment, growth companies with strong insider ownership can be particularly appealing as they often align management's interests with those of shareholders, potentially driving long-term value creation.
adventtr Quantum Computing ( QUBT ) was in focus on Tuesday as the quantum computing company said its first-quarter revenue surged nearly 9,000%. As such, Wedbush Securities believes the firm has become “bigger [and] better” due to acquisitions, and its story is still in the “early days.” Shares jumped nearly 25% in premarket trading, while other quantum stocks, such as Rigetti Computing ( RGTI ),...
adventtr Quantum Computing ( QUBT ) was in focus on Tuesday as the quantum computing company said its first-quarter revenue surged nearly 9,000%. As such, Wedbush Securities believes the firm has become “bigger [and] better” due to acquisitions, and its story is still in the “early days.” Shares jumped nearly 25% in premarket trading, while other quantum stocks, such as Rigetti Computing ( RGTI ), IonQ ( IONQ ), and D-Wave Quantum ( QBTS ) also rose. Rigetti also reported first-quarter results. “We continue to expect the recently completed acquisition of LSI to contribute between $20M to $25M in revenue in 2026, with LSI expected to bolster QUBT's semiconductor capabilities that will expand the company's addressable market and strengthen its ability to deliver integrated photonic solutions at scale,” Wedbush analyst Antoine Legault wrote in a note to clients. “Net, while we are encouraged by the company's 1Q26 results and forward commentary, we maintain our NEUTRAL rating and $12 PT on QUBT and continue to view the company as a 'show me' story given it remains at an earlier stage of development than its public peers with a considerably lower quantum hardware revenue base.” Hoboken, N.J.-based Quantum Computing said first-quarter revenue was $3.69M, which was above the $3.28M estimate. Revenue was aided by the acquisitions of Luminar Semiconductors in February 2026 and NuCrypt in March 2026. The company ended the quarter with $1.4B in cash and equivalents and a $16M contract backlog. More on Quantum Computing Quantum Computing Inc. (QUBT) Q1 2026 Earnings Call Transcript D-Wave Quantum Vs. Quantum Computing: Early Revenue Premium Masks Long-Term Parity Quantum Computing: Rating Upgrade After Q4 Inflection Quarter Biggest stock movers Tuesday: PLUG, HIMS, and more Quantum Computing outlines Fab 2 planning as Q1 revenue reaches $3.7M following Luminar and NuCrypt acquisitions
Keir Starmer was facing growing pressure to step down as Britain’s prime minister after dozens of members of Parliament, including Cabinet allies, joined the calls for him to set out a timetable for his departure. The pound extended losses and Gilts came under further pressure, with the yield on 10-year notes jumping beyond 5.10%. The yield on 30-year debt hit its highest level since 1998. The Ope...
Keir Starmer was facing growing pressure to step down as Britain’s prime minister after dozens of members of Parliament, including Cabinet allies, joined the calls for him to set out a timetable for his departure. The pound extended losses and Gilts came under further pressure, with the yield on 10-year notes jumping beyond 5.10%. The yield on 30-year debt hit its highest level since 1998. The Opening Trade has everything you need to know as markets open across Europe. With analysis you won't find anywhere else, we break down the biggest stories of the day and speak to top guests who have skin in the game. Hosted by Anna Edwards, Guy Johnson and Tom Mackenzie. (Source: Bloomberg)
A Spanish passenger evacuated from the cruise ship at the centre of a hantavirus outbreak has tested positive for the virus, Spain’s health ministry announced on Tuesday as the World Health Organization said it has now confirmed 11 cases, including three people from the cruise who died. The passenger with the new confirmed case of hantavirus was in quarantine in a military hospital in Madrid, wher...
A Spanish passenger evacuated from the cruise ship at the centre of a hantavirus outbreak has tested positive for the virus, Spain’s health ministry announced on Tuesday as the World Health Organization said it has now confirmed 11 cases, including three people from the cruise who died. The passenger with the new confirmed case of hantavirus was in quarantine in a military hospital in Madrid, where 13 other Spanish nationals evacuated on Sunday – who all tested negative for the virus – also are...
Lorado/E+ via Getty Images Co-authored with Beyond Saving The market indices are trading near all-time highs and are trading near all-time high valuations. Yardeni This is simply a fact. People can argue over whether there is something unique about the mega-caps driving the S&P 500 higher or whether something has changed that makes a 21x price/earnings an attractive valuation, but you can't argue ...
Lorado/E+ via Getty Images Co-authored with Beyond Saving The market indices are trading near all-time highs and are trading near all-time high valuations. Yardeni This is simply a fact. People can argue over whether there is something unique about the mega-caps driving the S&P 500 higher or whether something has changed that makes a 21x price/earnings an attractive valuation, but you can't argue that historically, the average of 21x P/E is much higher than usual. I tend to be a believer in history rhyming, and we can see on this chart what happened in the past when the P/E ratio for the S&P 500 was this high. Of course, that doesn't mean everything in the market is expensive. The red line above is the median P/E ratio, the point where 50% of companies fall below, and 50% of companies are above. Currently, that line is 18.5x price/earnings. In the stock market, I'm a bargain shopper at heart. I'm never paying +20x P/E for anything. My goal is to buy investments that are trading at a low valuation and collect dividends. If the valuation gets high, I'll sell and find something else that is inexpensive. Today, we're going to take a look at two companies that are trading at low valuations. These companies had some issues over the past five years that have left them cast aside by a market willing to pay a premium for the next shiny thing. Both companies are trading at bargain valuations that we expect will rise in the near to mid-future. Let's dive in! Pick #1: EPR – Yield 6.4% In our last article on EPR Properties ( EPR ) before earnings, we predicted : "We are confident that EPR has other irons in the fire and will be increasing its acquisition guidance, which will also lead to an increase in FFOAA (FFO As Adjusted) guidance for 2026. EPR is trading at only 10x FFOAA based on prior guidance. An increase in guidance and an increased expected growth rate should drive the price higher and inspire the market to trade EPR at a higher multiple." Sure enough, they increased g...
MicroStockHub/iStock via Getty Images Arvinas ( ARVN ) announced on Tuesday that the company and its partner, Pfizer ( PFE ), reached an agreement with Rigel Pharmaceuticals ( RIGL ) to sell global licensing rights to their jointly developed breast cancer therapy, Veppanu (vepdegestrant), to Rigel ( RIGL ). The protein degrader therapy was approved by the FDA earlier this month for a subset of adu...
MicroStockHub/iStock via Getty Images Arvinas ( ARVN ) announced on Tuesday that the company and its partner, Pfizer ( PFE ), reached an agreement with Rigel Pharmaceuticals ( RIGL ) to sell global licensing rights to their jointly developed breast cancer therapy, Veppanu (vepdegestrant), to Rigel ( RIGL ). The protein degrader therapy was approved by the FDA earlier this month for a subset of adults with breast cancer. Under the collaboration, Rigel ( RIGL ) will take responsibility for the launch and commercialization of Veppanu in the U.S. by giving $70M upfront to Arvinas ( ARVN ) and Pfizer ( PFE ). The duo will also receive $15M in additional payments, subject to the completion of certain development and manufacturing activities, as well as up to $320M in milestone payments and tiered royalties on net sales in the mid-teens to mid-20s. The companies will equally share the payments. As part of the deal, Rigel ( RIGL ) will also receive global rights to Veppanu, including rights to sublicense the drug in overseas territories to future partners. In exchange, Arvinas ( ARVN ) and Pfizer ( PFE ) will be eligible for a percentage of sublicensing revenue earned outside the U.S. The partnership further specifies that the duo will receive up to a $40M contribution from Rigel ( RIGL ) to continue their ongoing R&D activities related to vepdegestrant . The collaboration was announced in conjunction with Arvinas’ ( ARVN ) Q1 2026 results on Tuesday. More on Pfizer, Rigel Pharmaceuticals, etc. Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript Rigel Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation Pfizer Inc. (PFE) Q1 2026 Earnings Call Transcript FDA asks for feedback on repurposing drugs for new indications Arvinas Q1 2026 Earnings Preview
AndreyPopov/iStock via Getty Images Introduction In my last article on PayPal Holdings, Inc. ( PYPL ), I highlighted interest by a super investor with a Buffett-like mindset. Since then, PYPL has been my worst performer, trailing the S&P 500 by almost 50%. PYPL Performance since Previous Article (Seeking Alpha) A lot has changed besides the price movement, especially with former CEO Alex Chriss be...
AndreyPopov/iStock via Getty Images Introduction In my last article on PayPal Holdings, Inc. ( PYPL ), I highlighted interest by a super investor with a Buffett-like mindset. Since then, PYPL has been my worst performer, trailing the S&P 500 by almost 50%. PYPL Performance since Previous Article (Seeking Alpha) A lot has changed besides the price movement, especially with former CEO Alex Chriss being replaced by the former HP Inc. ( HPQ ) CEO, Enrique Lores. While the market did not like this decision, I think it's actually a wonderful hire since PYPL will now transition to a similar playbook to HPQ , which I have written about here. Slow growth, cheap valuations, accretive buybacks, and operational efficiency will be the name of the game moving forward. Because of this, I still am bullish on this ticker even with the recent performance. Essentially, PYPL may not need a return to hypergrowth to generate strong shareholder returns. The story here is much simpler in my opinion. The stock looks cheap, management is focused on reducing operating expenses, and the company continues aggressively repurchasing shares using billions in annual free cash flow. The market currently appears focused on slowing growth, margin pressure, and increasing competition from companies like Apple Pay, Stripe, Shopify, and Block. As a result, PayPal's valuation has compressed significantly over the past several years. However, the business itself still generates enormous amounts of cash flow and remains highly profitable. In my view, investors may be underestimating how powerful continued cost reductions and share repurchases can become when executed at depressed valuation levels. Management now appears focused on the right priorities. During the recent earnings call, CEO Enrique Lores discussed simplifying the organization, improving efficiency, using AI to reduce costs, and streamlining operations. Management expects these initiatives to generate at least $1.5 billion in gross run-rate sa...
Prelude Therapeutics press release ( PRLD ): Q1 GAAP EPS of -$0.13 beats by $0.12 . Revenue of $4.58M. More on Prelude Therapeutics Prelude Therapeutics prices $90M equity offering Seeking Alpha’s Quant Rating on Prelude Therapeutics Historical earnings data for Prelude Therapeutics Financial information for Prelude Therapeutics
Prelude Therapeutics press release ( PRLD ): Q1 GAAP EPS of -$0.13 beats by $0.12 . Revenue of $4.58M. More on Prelude Therapeutics Prelude Therapeutics prices $90M equity offering Seeking Alpha’s Quant Rating on Prelude Therapeutics Historical earnings data for Prelude Therapeutics Financial information for Prelude Therapeutics
At Holdings Channel, we have reviewed the latest batch of the 60 most recent 13F filings for the 03/31/2026 reporting period, and noticed that Uber Technologies Inc (Symbol: UBER) was held by 24 of these funds. When hedge fund managers appear to be thinking alike, we find it is
At Holdings Channel, we have reviewed the latest batch of the 60 most recent 13F filings for the 03/31/2026 reporting period, and noticed that Uber Technologies Inc (Symbol: UBER) was held by 24 of these funds. When hedge fund managers appear to be thinking alike, we find it is
(RTTNews) - Japan's Panasonic Holdings Corp. (PCRFF, PCRFY, 6752.T) reported Tuesday lower profit in fiscal 2026 with weak net sales. Looking ahead for fiscal 2027, the company projects higher earnings, but lower net sales.
(RTTNews) - Japan's Panasonic Holdings Corp. (PCRFF, PCRFY, 6752.T) reported Tuesday lower profit in fiscal 2026 with weak net sales. Looking ahead for fiscal 2027, the company projects higher earnings, but lower net sales.
Thyssenkrupp AG ( TYEKF ): 1H EPS for the period ended March 31, 2026: loss of €0.57 vs profit of €0.17 a year earlier Sales for the period ended March 31, 2026: €15.57B, down 5% Y/Y Order intake for the period ended March 31, 2026: €18.32B, down 11% Y/Y More on thyssenkrupp AG thyssenkrupp AG (TKAMY) Q1 2026 Earnings Call Transcript Thyssenkrupp, Jindal put steel stake talks on ice as conditions ...
Thyssenkrupp AG ( TYEKF ): 1H EPS for the period ended March 31, 2026: loss of €0.57 vs profit of €0.17 a year earlier Sales for the period ended March 31, 2026: €15.57B, down 5% Y/Y Order intake for the period ended March 31, 2026: €18.32B, down 11% Y/Y More on thyssenkrupp AG thyssenkrupp AG (TKAMY) Q1 2026 Earnings Call Transcript Thyssenkrupp, Jindal put steel stake talks on ice as conditions shift Thyssenkrupp AG GAAP EPS of -€0.57, revenue of €7.19B; sets financial expectations for FY26 Historical earnings data for thyssenkrupp AG Dividend scorecard for thyssenkrupp AG
Binance reported that its AI-powered security systems helped prevent $10.53 billion in potential user losses from early 2025 through Q1 2026. Google identified a zero-day ...
Binance reported that its AI-powered security systems helped prevent $10.53 billion in potential user losses from early 2025 through Q1 2026. Google identified a zero-day ...
As artificial intelligence (AI) stocks keep climbing, a practical question emerges amid the excitement: Who will provide electricity for all these data centers? Certainly not the grid, at least not without some help. U.S. power demand is now expected to grow for four straight years through 2027. Data center electricity use, meanwhile, could double or triple by 2028, according to Lawrence Berkley N...
As artificial intelligence (AI) stocks keep climbing, a practical question emerges amid the excitement: Who will provide electricity for all these data centers? Certainly not the grid, at least not without some help. U.S. power demand is now expected to grow for four straight years through 2027. Data center electricity use, meanwhile, could double or triple by 2028, according to Lawrence Berkley National Laboratory. Much of the grid, for its part, was made in the decades after World War II and will likely give up the ghost if we strain it any further. Clearly, the world will need fresher solutions to a future power bottleneck. And Nano Nuclear Energy (NASDAQ: NNE) could play a huge role in filling the gap. Continue reading